Daewoong Pharmaceutical Announces Successful ‘Extra Strength’ Results of US Phase 2 Clinical Trial for High-dose Administration of Botulinum Toxin
Daewoong Pharmaceutical is proud to announce the successful completion of a Phase 2 clinical trial for its botulinum toxin type-A product in the United States. Evolus announced the long-term effects…
